Yahoo · Oct 30, 2026
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.
CR
NASDAQ · CRSP
CRISPR Therapeutics AG
Healthcare · Biotechnology
$49.99
Up+$1.92 (+3.84%)
Updated Nov 4, 2026, 6:13 PM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.08B
- P/E ratio
- -10.81
- Dividend yield
- 0.00%
- 52-week range
- $44.12 – $63.45
- Volume
- 1.29M
- Avg. volume
- 2.56M
Price performance · CRSP
CRSP price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CRSP closed at $49.99 after 21 trading sessions, down 7.43% for the selected period.
- Last close
- $49.99
- Period change
- -7.43%
- Period low
- $49.01
- Period high
- $54.26
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $50.26 | $51.86 | $49.62 | $49.99 | 1.29M |
| Nov 2, 2026 | $51.90 | $52.1216 | $49.7001 | $49.99 | 1.03M |
| Oct 30, 2026 | $53.27 | $54.10 | $50.60 | $51.42 | 1.17M |
| Oct 29, 2026 | $54.11 | $55.82 | $53.30 | $54.26 | 1.31M |
| Oct 28, 2026 | $50.48 | $54.17 | $50.10 | $54.11 | 1.13M |
| Oct 27, 2026 | $49.14 | $51.55 | $48.75 | $51.47 | 1.17M |
| Oct 26, 2026 | $49.35 | $50.11 | $48.65 | $49.01 | 1.07M |
| Oct 23, 2026 | $49.31 | $49.68 | $48.02 | $49.39 | 1.93M |
| Oct 22, 2026 | $50.14 | $51.05 | $49.36 | $49.99 | 906.11K |
| Oct 21, 2026 | $50.13 | $50.94 | $49.5538 | $50.50 | 1.17M |
| Oct 20, 2026 | $48.87 | $50.3299 | $47.36 | $49.88 | 2.16M |
| Oct 19, 2026 | $49.83 | $50.30 | $49.09 | $50.04 | 1.18M |
| Oct 16, 2026 | $51.20 | $51.36 | $49.045 | $49.25 | 1.52M |
| Oct 15, 2026 | $50.00 | $52.3725 | $49.76 | $51.52 | 1.35M |
| Oct 14, 2026 | $49.67 | $50.78 | $48.91 | $50.22 | 1.71M |
| Oct 13, 2026 | $51.01 | $51.11 | $49.77 | $50.10 | 1.34M |
| Oct 12, 2026 | $52.91 | $53.21 | $51.40 | $51.55 | 1.11M |
| Oct 9, 2026 | $50.82 | $54.07 | $50.52 | $53.39 | 1.47M |
| Oct 8, 2026 | $51.51 | $53.54 | $50.02 | $50.44 | 2.87M |
| Oct 7, 2026 | $53.00 | $54.59 | $52.27 | $52.35 | 1.68M |
| Oct 6, 2026 | $60.385 | $60.68 | $53.7427 | $54.00 | 2.63M |
Latest CRSP news
The latest Smart Investors Daily articles mentioning CRSP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CRSP research
Overview
Company profile and research snapshot.
Company profile
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $66.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 3, 2026 | Needham | Buy | — |
| Oct 15, 2026 | UBS | Neutral | — |
| Aug 31, 2026 | Citizens | Market Outperform | — |
| Aug 31, 2026 | Needham | Buy | — |
| Aug 25, 2026 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.
Yahoo · Oct 25, 2026
Learn Why The Bull Case For CRISPR Therapeutics Stock Could Change Following CFO Change
CRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer and principal financial officer on October 19, 2026, following his tenure as Senior Vice President of Finance and a prior decade in assurance services at Ernst & Young. The shift from Raju Prasad to an internally developed finance leader comes as CRISPR Therapeutics faces changing earnings projections and ongoing investment in its gene based medicine pipeline. The focus now turns to how this CFO transition reshapes...
Yahoo · Oct 25, 2026
CRISPR Therapeutics (CRSP) Promotes Andrew Silver To CFO As Raju Prasad Resigns
CRISPR Therapeutics (NasdaqGM:CRSP) has promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Outgoing CFO Raju Prasad, Ph.D., has resigned from his role, also effective October 19, 2026. Silver steps into the finance chief role after serving within CRISPR Therapeutics, bringing internal experience to the transition. The CFO handover from Raju Prasad to Andrew J. Silver is only one piece of CRISPR Therapeutics' broader story today. Check out 2 other big wins that...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
